10 ML sebelipase alfa 2 MG/ML Injection [Kanuma] — RxCUI 1726984
RxNorm drug concept · Semantic branded drug
RxCUI 1726984
Semantic branded drug · SBD
● Current RxNorm concept 1 FDA product
1 package NDC
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1726984
Official name10 ML sebelipase alfa 2 MG/ML Injection [Kanuma]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as10 ML Kanuma 2 MG/ML Injection; Kanuma 20 MG in 10 ML Injection; Kanuma 20 MG per 10 ML Injection
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)132 prescriptions · 4 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
🕸️ Concept Web — How 10 ML sebelipase alfa 2 MG/ML Injection [Kanuma] Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
10 ML sebelipase alfa 2 MG/ML Injection [Kanuma]
RxCUI 1726984 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Sebelipase alfa
1726975IN
-
Sebelipase alfa
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Kanuma
1726980BN
-
Kanuma
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Sebelipase alfa Injection
1726978SCDF -
Sebelipase alfa Injectable Product
1726977SCDG -
Sebelipase alfa Injection [Kanuma]
1726982SBDF -
Kanuma Injectable Product
1726983SBDG -
Injection
1649574DF -
Injectable Product
1151126DFG
-
Sebelipase alfa Injection
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
10 ML sebelipase alfa 2 MG/ML Injection
1726979SCD -
Sebelipase alfa 2 MG/ML
1726976SCDC -
Sebelipase alfa 2 MG/ML [Kanuma]
1726981SBDC
-
10 ML sebelipase alfa 2 MG/ML Injection
Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
10 ML sebelipase alfa 2 MG/ML Injection
SCD · 1726979 -
Sebelipase alfa 2 MG/ML
SCDC · 1726976 -
Sebelipase alfa Injection
SCDF · 1726978 -
Sebelipase alfa Injectable Product
SCDG · 1726977
Brand-Name Concepts
-
Sebelipase alfa 2 MG/ML [Kanuma]
SBDC · 1726981 -
Sebelipase alfa Injection [Kanuma]
SBDF · 1726982 -
Kanuma Injectable Product
SBDG · 1726983 -
Kanuma
BN · 1726980
📦 FDA Products & Package NDCs
1 product · 1 package NDC
1 package NDC map to RxCUI 1726984 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 25682-0007-01 | 1 VIAL, GLASS in 1 CARTON (25682-007-01) / 10 mL in 1 VIAL,... | KANUMA | Alexion Pharmaceuticals, Inc. | 2015-12-08 |
Observed labelers:
Alexion Pharmaceuticals, Inc. (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.